Skip to main content

IgAN

3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ADARx Pharmaceuticals
ADARx PharmaceuticalsCA - San Diego
1 program
1
ADX-038 Dose Level 2Phase 21 trial
Active Trials
NCT06989359Recruiting45Est. Jun 2029
Fosun Pharma
Fosun PharmaAustralia - Sydney
1 program
1
FXS6837 Dose 1Phase 21 trial
Active Trials
NCT07502638Not Yet Recruiting60Est. Nov 2027
Sitala Bio
Sitala BioUK - Cambridge
1 program
1
STL303Phase 21 trial
Active Trials
NCT07606352Not Yet Recruiting15Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
Sitala BioSTL303
Fosun PharmaFXS6837 Dose 1
ADARx PharmaceuticalsADX-038 Dose Level 2

Clinical Trials (3)

Total enrollment: 120 patients across 3 trials

Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

Start: Jun 2026Est. completion: Sep 202715 patients
Phase 2Not Yet Recruiting

FXS6837 for the Treatment of IgAN Patients

Start: Mar 2026Est. completion: Nov 202760 patients
Phase 2Not Yet Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Start: Aug 2025Est. completion: Jun 202945 patients
Phase 2Recruiting

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 120 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

IgAN | Pipeline & Competitive Landscape | Formulate